Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | PDE8B | O95263 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803668 | 0.90 | CHRM4 (0.40) | CHRM4KDM4ESMN1; SMN2ACHEDRD2 | |
| SCHEMBL803679 | 0.82 | KDM4E (0.53) | CYP1A2CYP2D6ALDH1A1LMNAKDM4E | |
| SCHEMBL18713078 | 0.79 | LMNA (0.36) | CHRM4CYP2D6ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL803095 | 0.77 | HSD11B1 (0.47) | HIF1AACHE | |
| SCHEMBL18390910 | 0.77 | ACHE (0.43) | CHRM4ALDH1A1LMNAKDM4EACHE | |
| SCHEMBL803402 | 0.77 | TNKS (0.36) | CHRM4CYP2D6LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL803083 | 0.76 | CCR3 (0.58) | CYP1A2CYP2D6ALDH1A1ACHE | |
| SCHEMBL803403 | 0.76 | KDM4E (0.36) | CHRM4CYP1A2CYP2D6HIF1ALMNA | |
| SCHEMBL803678 | 0.76 | CHRNB2 (0.54) | ALDH1A1KDM4E | |
| SCHEMBL803676 | 0.75 | LMNA (0.50) | CYP1A2ALDH1A1LMNAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | CHRM4 469/4885CYP1A2 1988/4885CYP2D6 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.